If you are a patient with colorectal or gastro-oesophageal cancers and you are interested in clinical trials, ask your treating oncologist if a referral to us makes sense. 🔥Highly anticipated trials with novel KRAS / RAS-inhibitors 💊 are expected to open late 2025 (2/2).

‼️The GI team at St Barts 🏥offers a range of clinical trials for patients with all stages of stomach/oesophageal cancers and colorectal cancers. We have one of the largest number of trials with cutting-edge Antibody Drug Conjugates (ADCs) and immunotherapies in the UK. (1/2).

RT @AdamJanuszewski: ‘If this was a HR of a drug intervention you would get a standing ovation’ . Fascinating data presented #ASCO25 on imp….

“3-year structured exercise program initiated soon after adjuvant chemotherapy.for colon cancer resulted in significantly longer disease-free survival and findings.consistent with longer overall survival.” Magnitude of efficacy similar ‼️to adjuvant therapy. Let’s get active!

Effective across PDL1 subgroups but somewhat disappointing efficacy in diffuse subtype tumours << we need trials for these (CLDN18 etc)

#ASCO2024 Long awaited Matterhorn phase 3 trial results of durvalumab added to periop FLOT in early stage gastric/GOJ adenocarcioma; positive trial with a HR of 0.71 favouring the addition of immunotherapy. 2 year EFS of 67 vs 59%. OS immature. new standard of care pending OS

The next questions are whether immunotherapy alone can do the same as chemo + immunotherapy as shown in ATOMIC, and if neoadjuvant immunotherapy is more effective.

Major limitation: 6 months of chemo as used in the trial is not the standard for most patients.

#ASCO25 🔥 Plenary presentation of ATOMIC phase 3 adjuvant chemo + atezolizumab vs chemo alone in MMRd colon cancer: positive and practice changing trial with HR 0.5

#ASCO25 Always expect the unexpected in trials with EGFR antibodies in CRC: Triplete phase 3 trial shows significantly longer OS (8.1 mo abs difference) for first line FOLFOXIRI Pani vs FOLFOX Pani, despite no difference in RR, PFS. New option for fit RAS/BRAF wt

Without stronger and lasting efficacy, the future of cellular therapies for solid tumours remains unclear. But kudos to the investigators who completed this complex work!.

PFS significantly improved with CAR-T va standard of care - benefit is nevertheless modest, although this is predominantly a third line population.

#ASCO25 Here is the design of this CLDN18.2 CAR-T trial. Impressive numbers for an early-stage cellular therapy trial

Next up is a very interesting one. A randomised CAR T cells trial in gastric cancer

#ASCO25 Destiny Gastric 04 phase 3 rct of 2nd line TdXD vs PAC-Ram in HER2+ gastric/goj cancer shows significant OS benefit: 14.7mo versus 11.4mo median. Likely practice changing in HER2+.

Benefit mainly in SCC subtype and PDL1 positive

Curve separation maintained, suggesting that additional pts get cured. Subgroup analysis indicates that mainly SCC benefit

#ASCO25 Checkmate 577 trial first overall survival data readout: 12 months of adjuvant Nivo after CRT and surgery for Oeosphageal/GOJ cancer shows 16.4m median OS increase. Only significant if corrected for subsequent therapy.

RT @BartsECMC: Attendees at our @BartsECMC Patient event are currently listening to Prof @MarcoGerlinger @BartsGI_Cancer talking all about….

🔥Just opened: 4 year CLINICAL LECTURERSHIP position in HISTOPATHOLOGY @NHSBartsHealth and @QMBCI in London: for ST3/4 registrars who already hold a PhD/MD. Great opportunity for a deep dive into the immunobiology of MMRd GI cancers. Deadline 11/04 10am